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Substituted chroman-4-ones la-lOa on catalytic reduction with Baker's Yeast give (S)-chroman-4-
ols Ic-I Ic with high enantioselectivity. The absolute configuration has been determined by specific
rotation and CD spectra.
The enantioselective reduction of carbonyl
compounds using bio-catalysts such as isolated
pure enzymes or whole cells such as yeasts,
bacteria and fungi continue to attract the attention
of synthetic organic chemists 1.2. Whole cell yeast
catalysed reactions are particularly attractive in
this respect as yeast is readily and cheaply
available bio-catalyst and the use of whole cells
obviates the need for the addition of expensive co-
factors. It is now known that, in general, the
Baker's yeast catalysed enantioselective reduction
of carbonyl compounds proceed in accordance
with the Prelog's rule', Earlier, (S)-chorman-4-01
le was obtained by the lipase catalysed kinetic
resolution of racemic chroman-a-ol Ib".
Substituted chroman-4-ones, a class of oxygen
heterocyclics, are common among natural products
and are extensively used as synthetic
intermediates'. Earlier Holl et al.6 studied the
Mortierella isabellina catalysed reduction of
chroman-4-one la and thiochroman-4-one and the
products are (S)-chroman-4-ol le and (S)-
thiochroman-4-ol in 84% ee and 88% ee
respectively. There are no reports in the literature
regarding the enantioselective reduction of
chroman-4-ones using Baker's yeast. We report
herein the bio-reduction of several substituted
chroman-4-ones la-lOa using Baker's yeast
(Scheme I).
In a typical experiment, chroman-4-ones la-lOa
(0.3 mol) dissolved in ethanol (5 mL) was slowly
added during 24 hr to a citrate buffer 0.05 M (300
ml) containing Baker's yeast beads immobilised in
calcium alginate" and stirred at RT for 48-168 hr,
':*>" -~i-~;-:u-:~-:b-:~-:a_f:-:_. ,:!~Q"
R4 0 pH= 4,5-5·0 R4 H OH
48-168 hrs.
(10-110) (Ie-lie)
I a,b,c = RI ,R2,R3,R4,R5=H
2 a,b,c = RI ,R2,R4,R5=Hj R3=CI
3 a,b,c = RI ,R2,R4 ,R5=H; R3=CH3
4 a,b,c = RI, R2,R3 ,R5::,Hj R4=CH3
5 a,b,c = R2,R3,R4,R5=Hj RI =CH3
6 a,b,c = RI ,R3,R4 ,R5=Hj R2=OCH3
7 a,b,c = R3,R4,R5=Hj RI=CH3,R2.=OCH3
8 a,b,c = RI, R2,R4,R5=HjR3=Br
9a,b,c =RI,R3,R4,R5=HjR2=CI
10 a,b,c = RI ,R3,R4 ,R5=H j R2=CH20-@
II a,b,c = RI,R2,R4=H;R3=CI;R5=~
Scheme I
maintaining. pH of the reaction mixture at 4.5-5.0
by the addition of ammonia. The reduction was
monitored by TLC by comparison with authentic
racemic chroman-4-ols lb-lOb. When there is no
further increase in the product concentration, the
supernatant solution was decanted, extracted with
ethyl acetate and column chromatographed on
silica gel. The yields of le-IOe was 30-40% (Table
I). Racemic Ib-lOb needed to moriitor the bio-
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Table I--Characterization data of (S)-chroman-4-ols I c-I Oe
Compel Reaction %of %ofee Specific CD 9xlO-l
time Chemical (from chiral rotation data (deg.cm'.d. mol:')
(hr) yield HPLC) (in CHCll)
Ie 48 30 88.4 -40.00 (-)228 nm (-) 220x10-l
(c,O.5%) (-)280 nm (-) 48x10-l
2e 96 40 73.3 -30.30 (-)232 nm (-) 293x10-l
(c,0.33%) (-)240 nm (-) 79xlO-l
3e 72 34 44.2 -2.70 (-)230 nm (-) 21 Ox1o-
(c,2%) (-)285 nm (-) 59xlO-l
4e 168 37 32.5 -28:04 (-)234 nm (-) 200x io-
(c,0.97%) (-)270 nm (-) 25x 10-l
5e 72 36 10.3 -2.00 (-)233 nm (-) 234x 10-l
(c,0.5%) (-)279 nm (-) 52x10-l
6e 96 30 74.1 -8.80 (-)229nm (-) 249xlO-l
(c,0.05%) (-)262 nm (-) 27x10-l
7e 48 30 25.0 -8.46 (-)243 nm (-) 246x IO-l
(c,0.26%) (-)274 nm (-) 33x IO-l
ge 48 30 53.1 -25.00 (-)233 nm (-) 236x IO-l
(c,I%) (-)275 nm (-) 47x IO-l
IOe 168 35 65.8 -9.00 (-)236 nm (-) 220x 10-l
(c,I%) (-) 203 nm (-) 39x IO-l
reduction were obtained by the NaBH4 reduction
of la-lOa using reported methods.
The absolute configuration of the Baker's yeast
reduction products Je-Hle as S is determined from
specific rotation and CD spectra. Earlier Maja et
al.' reported the CD spectral data for I e. It showed
negative cotton effect with bands at 228 and 280
nm. Ic-Hlc showed negative CD spectral bands
similar to the reported for Ic (Table I). The % ee
of the (S)-chroman-4-0Is is determined by chiral
HPLC. Table I gives the % chemical yields, % ee,
specific rotation and CD spectral data of Baker's
yeast reduction products. Good enantioselectivity
was observed for unsubstituted chroman-4-one la
and 6- and 7-substituted chroman-4-ones 2a, 6a,
8a. The bio-reduction of prochiral chroman-4-ones
proceed in accordance with Prelog's rule, with the
hydride delivered to the re-face. This study shows
that Baker's yeast reduction of chroman-4-ones
la-lOa offers a new route to optically active (S)-
chroman-t-ols I c-I Oe.
Experimental Section
Baker's yeast, Eagle brand, India was used.
Specific rotations were recorded on JASCO J-20
polarimeter. and CD spectra on JASCO J-20
spectropolarimeter. Chiral HPLC was done on
Shimadzu LC 6A with Chiracel OD column
(2S0xS mm), using n-hexane: isopropanol (98:2).
IH (200 MHz) and l3C N!vfR (50.3) MHz) were
recorded on Varian Gemini 200 NMR
spectrometer.
The chiral HPLC of (±) racemic chroman-4-ols
Ib-IOb as well as the Baker's yeast reduction
products le-IOe was recorded on Chiracel O.D.
column (2Sx0.46 cm, Diacel, Japan) under
following conditions: flow 0.5 mLimin using 2%
isopropanol in n-hexane as the eluent. The
retention times (min) were (±) lb 23.4 and 26.9,
(±) 2b 13.0 and 14.1, (±) 3b 18.0 and 20.3, (±) 4b
10.6 and 13.5, (±) 5b, 13.5 and 16.9, (f) 6b 22.0
and 27.6, (±) 7b 16.3 and 18.4, (±) 8b 13.2 and
16.1, (±) 9b 13.0 and 14.5, (±) lOb 17.2 and 18.3;
(±) llb 17.7 and 20.2; (-) Ic 23.6 and 27.0, (-) 2e
13.1 and 14.7, (-) 3e 18 and 20.4, (-)4e 10.7 and
13.9, (-) 5e 13.9 and 17.1, (-)6e 22.1 and 27.6, (-)
7c 16.4 and 18.7, (-) 8c 13.8 and 15.2, (-) 9c 13.1
and 14.6, (-) IOe 17.4 and 18.4; (-) lle 17.9 and
20.6.
Chroman-4-ones la-lOa are already known",
Ib-IOb were obtained by NaBH4 reduction of
chroman-4-ones La-Hla". (±) Chroman-s-ols (Ib,
2b, 3b, 6b, 8b, 9b, lOb) are already known".
Baker's yeast beads immobilised in calcium
alginate are prepared as per reported method':".
General procedure for the Baker's yeast
mediated synthesis of (S)-ehroman-4-o1s. Baker's
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yeast (lOg) immobilised in calcium alginate to
give beads, was kept in 20% glucose solution for
48 hr The beads were filtered, washed with water
and transferred to a flask containing 0.05 M citrate
buffer (300 mL) with pH 4.5-5.0. Chroman-4-ones
la-lOa (0.3 mol) dissolved in ethanol (5 ml) were
added slowly during 24 hr The reaction mixture
was gently stirred at RT for 48-168 hr The pH of
the reaction mixture was maintained by addition of
3 N NH3. The progress of the reaction was
monitored by TLC by comparison with racemic
chroman-4-ols. When there is no further increase
in the concentration of the product, the supernatant
solution decanted and extracted with ethyl acetate
(200 ml), dried and chromatographed on silica gel.
Chroman-4-ols Ic-Iflc were obtained in 30-40%
yield.
lb: IR: 3375 em"; IH NMR (CDC13): & 4.15 (m,
2H, OCHz), 1.95 (m, 2H, CHz), 4.60 (t, J = 2 Hz,
1H, H-4), 3.0 (bs, 1H, OH), 6.82 (m, 2H, H-5, 8),
7.20 (m, 2H, H-6); l3C NMR (CDC13): s 62.0 (C-
2), 37.1 (C-3), 63.0 (C-4), 124.4 (C-4a), 130.0 (C-
5), 121.0 (C-6) 130.0 (C-7), 117.0 (C-8), 135.0 (C-
8a). MS: (m/z) 150 (100), 121 (75), 105 (20), 77
(25) and 51 (20).
2b: IR: 3352 em"; IH NMR (CDC13): s 4.18
(m, 2H, OCHz), 2.00 (m, 2H, CHz), 4.65 (bs, IH,
H-4), 1.90 (bs, 1H, OH), 7.20 (d, J = 2 Hz, 1H, H-
5), 7.08 (dd, J = 10 Hz, 2 Hz, 1H, H-7), 6.70 (d, J
= 10 Hz, 1H, H-8); l3C NMR (CDC13): & 62.1 (C-
2),)0.3 (C-3), 63.0 (C-4), 125.7 (C-4a), 130.0 (c~
5), 125.2 (C-6), 129.2 (C-7), 118.5 (C-8), 153.3
(C-8a). MS: (m/z) 184 (90), 165 (20), 156 (70),
107 (20), 103 (20), 75 (20), 63 (25) and 39 (20).
3b: IR: 3348 ern"; IH NMR (CDC13): s 4.15 (m,
2H, OCHz), "1.98 (m, 2H, CHz), 4.60 (t, J=2Hz, IH,
H-4), 2.40 (bs, 1H, OH), 7.02 (d, J=2Hi, IH, H-5),
6.95 (dd, J=10 Hz, 2 Hz, IH, B-7) 6.60 (d, J=10
Hz, IH, H-8), 2.26 (bs, 3H, CH3); l3C NMR
(CDC13): & 62.0 (C-2), 31.0 (C-3), 63.0 (C-4),
124.0 (C-4a), 130.2 (C-5), 130.0 (C-6), 130.0 (C-
7), 117.0 (C-8), 152,3 (C-8a), 20.1 (CH3)' MS:
(m/z) 164 (100), 149 (70), 135 (.80), 121 (25), 107
(30), 91 (20), 77 (30) and 51 (20).
4b: IR: 3334 cm'; IH NMR (CDC13): s 4.24 (m,
2H, OCHz), 2.10 (m, 2H, CHz,), 4.70 (bs,lH, H-4),
1.65 (bs, iu, OR), 6.74 (dd, J = 10 Hz, 2Hz, lH,
H-6), 6.74 (dd, J=10 Hz, 2 Hz, 1H, H-7), 7.00 (m,
IH, H-8) 2.20 (m, 3H, CH3); BC NMR (CDC13): s
62.0 (C-2), 31.0 (C-3), 63.2 (C-4), 123.8 (C-4a),
126.3 (C-5), 127.3 (C-6), 131.0 (C-7), 120.0 (C-8)
153.0 (C-8a), 16.0 (CH3)'
5b: R: 3299 cm'; IH NMR (CDC13): s 4.20 (m,
2H, OCHz), 2.02 (m, 2H, CHz), 4.70 (bs,lH, H-4),
1.72 (bs, 1H, OH), 7.21 (m, 1H, H- 5) 6.64 (m, 1H,
H-6) 6.64 (m, 1H, H-7), 2.28(s, 3H, CH3); l3C
NMR (CDC13): & 61.6 (C-2), 30.9 (C-3), 62.9 (C-
4), 123.8 (C-4a), 129.1 (C-5), 129.9 (C-6), 130.1
(C-7), 116.7 (C-8) 152.2 (C-8a), 20.4 (CH3)'
6a: IR: 3336 ern"; IH NMR (CDC13): s 4.28 (m,
2H, OCHz), 2.05 (m, 2H, CHz,), 4.75 (bs,lH, H-4),
1.95 (bs, 1H, OH), 7.20 (d, J=10 Hz, 1H, H-5),
6.52 (dd, J=lO Hz, 2 Hz, 1H, H-6), 6.38 (d, J=2
Hz, 1H, H-8), 3.80 (s, 3H, OCH3); 13C NMR
(CDC13): & 61.7 (C-2), 30.8 (C-3), 62.0 (C-4),
130.8 (C-4a), 131.0 (C-5), 116.8 (C-6), 130.9 (C-
7), 101.1 (C-8) 155.5 (C-8a), 55.1.(OCH3)'
7b: IR: 3375 ern"; IH NMR (CDC13): s 4.38 (m,
2H, OCHz), 2.10 (m, 2H, CHz), 4.80 (bs,lH, H-4),
1.75 (d, J=6 Hz, 1H, OH~ 7.15 (d, J=10 Hz, 1H,
H-5), 6.55 (d, J=10 Hz, 1H, H-6), 3.90 (s, 3H,
OCH3)' 2.15 (s, 3H, CH3); 13 C NMR (CDC13): s
61.9 (C-2), 30.9 (C-3), 63.4 (C-4), 117.3 (C-4a),
127.0 (C-5), 103.1 (C-6), 153.1 (C-7), 113.7 (C-8)
158.3 (C-8a), 55.7 (OCH3), 8.0 (CH3)'
8b: IR: 3389 cm'; IH NMR (CDC13): s 4.25 (m,
2H, OCH2), 2.05 (m, 2H, CH2,), 4.75 (m,lH, H-4),
1.75 (bs, 1H, OH), 7.44 (d, J=2 Hz, 1H, H-5), 7.28
(dd, J=10 Hz, 2 Hz, lH, H-7), 6.72 (d, J=10 Hz,
m, H-8). 13C NMR (CDC13): s 62.0 (C-2), 30.3
(C-3), ·62.7 (C-4), 126.2 (C-4a), 132.4 (C-5), 112.3
(C-6), 132.1 (C-7), 119.0 (C-8) 153.8 (C-8a). MS:
(m/z) 228 (100),211 (25),200 (75), 149 (75), 131
(20), 107 (40), 103 (15),91 (15) and 63 (30).
9b: IR: 3297 ern"; IH NMR (CDC13): & 4.18 (m,
2H, OCH2), 2_00 (m, 2H, CH2), 4.68 (bs, 1H, H-4),
1.68 (bs, 1H, OH), 7.12 (d, J=10 Hz, 1H, H-5),
6.80 (m, 1H, H-6), 6.80 (m, IH, H-8); l3C NMR
(CDC13): 8 62.0 (C-2), 30.8 (C-3), 62.9 (C-4),
122.2 (C-4a), 130.5 (C-5), 121.0 (C-6), 130.1 (C-
7),_96.3 (C-8) 154.1 (C-8a). MS: (m/z) 184 (95),
165 (35),155 (100),149 (95), 131 (10), 103 (5), 91
(10),75 (20);'63 (15) and 51 (20).
lOb: IR: 3364 cm'; IH NMR (CDC13): 8 4.18
(m, 2H, OCH2), 2.00 (m, 2H, CH2,), 4.63 (bs, 1H,
H-4),1.52 (bs, 1R, OR), 7.10 (d, J=10 Hz, 1H, H-
5),6.47 (dd, J=10 Hz, 2 Hz, IH, H-6), 6.32 (d, 1=2
Hz, IH, H-8), 4.95 (s, 2H, OCH2) , 7.30 (m, 5H,
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Ph);13C NMR (CDCl3): s 61.7 (C':2), 30.8 (C-3),
61.7 (C-4), 117.1 (C-4a), 128.4 (C-5), 108.3 (C-6),
159.7, (C-7) l02.3 (C-8) 155.5 (C-8a). 69.7
(OCH2), 127.2, 128.4, 136.8 130.5 (Ph).
llb: IR: 3274 cm'; IHNMR (CDCl3): 04.85 (s,
2H, OCH2), 5.15 (d, J=8 Hz, 1H, H-4), 1.90 (bs,
lH, OH), 7.10-7.50 (m, 1H, H-5), 7.10-7.50 (m,
lH, H-5), 7.10-7.5Q (m, 1H, H-1), 6.74 (d, J=9 Hz,
1H, H-8), 6.90 (lH, =CH), 7.10-7.50 (m, 5H, Ph).
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